Psychometric properties of the German version of the Leicester Cough Questionnaire in sarcoidosis

Schupp, Jonas C.; Fichtner, Uwe; Frye, BC; Heyduck-Weides, Katja; Birring, Surinder S.; Windisch, Wolfram; Criée, Carl-Peter; Müller–Quernheim, Joachim; Farin, Erik

doi:10.1371/journal.pone.0205308

Cited by 13 publications

(21 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So, reliability of the Serbian verssion of the LCQ proved to be excellent. Th e subscale "physical" was the one with the weakest performance regarding internal consistency and it is in accordance with the results of Schupp and coauthors who validated the German version of the LCQ among 200 sarcoidosis patients [8]. Cronbach's alpha coeffi cients were similar with those in our study.…”

Section: Lcq -Physicalsupporting

confidence: 92%

“…Recently, more attention has been paid to the cough in patients with sarcoidosis and we now have a validated tool -Leicester Cough Questionnaire (LCQ) for measuring this important symptom [6]. Currently only a few studies used LCQ for assessing cough in sarcoidosis patients [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

“…Th e LCQ has been translated into several languages including Dutch, Korean, Lithuanian, Mandarin, Polish, Portuguese, German and Spanish, and validated in corresponding cohorts [10][11][12][13][14][15][16][17][18][19]. It has been also validated for diff erent diseases, like chronic cough itself, cystic fi brosis including aff ected children, bronchiectasis, COPD [17,[20][21][22], and recently for sarcoidosis [8]. A validated Serbian version does not exist, so our aim was to translate and validate Serbian version of the LCQ in sarcoidosis patients in order to provide an instrument for future multinational studies on chronic cough in sarcoidosis patients in particular.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Psychometric characteristics of the Serbian version of the Licester Cough Questionnaire in sarcoidosis patients

Gvozdenovic¹,

Mihailović-Vučinić²,

Vukovic³

et al. 2019

Hosp Pharm Int Multi J

View full text Add to dashboard Cite

Introduction: Cough is frequent symptom in sarcoidosis and there are no specifi c tools for measurement of its severity in Serbia. Aim: The goal of this study was to translate and validate the Serbian version of the Leicester Cough Questionnaire (LCQ) in a population of sarcoidosis patients. Methods: After the LCQ forward-backward translation process, in the cross-sectional study in 275 (180 female) sarcoidosis patients Serbian version of the LCQ was administered together with other standardized instruments for measurement of Patient Reported Outcomes (PROs)-symptoms of dyspnea (assessed by MRC and Borg scales) and fatigue (measured by Fatigue Assessment Scale and List of Daily Activities), and patients' health status (assessed by generic tool-15D). Pulmonary function tests (spirometry and diff using capacity for carbon monoxide) were also measured. Results: Serbian LCQ version showed excellent internal consistency (Cronbach's alpha of its diff erent scores ranged between 0.901 for physical domain and 0.951 for the total score). Concurent validity assessed by correlations of all LCQ scores with other PROs and pulmonary function tests was very good, since all these correlations were statistically signifi cant. Conclusions: Our results confi rmed that the Serbian version of LCQ is a valid instrument to monitor the infl uence of chronic cough on quality of life in sarcoidosis patients.

show abstract

Section: Lcq -Physicalsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Psychometric characteristics of the Serbian version of the Licester Cough Questionnaire in sarcoidosis patients

Gvozdenovic¹,

Mihailović-Vučinić²,

Vukovic³

et al. 2019

Hosp Pharm Int Multi J

View full text Add to dashboard Cite

show abstract

“…PROMs assessing cough in sarcoidosis include the Leicester Cough Questionnaire (LCQ) [179][180][181][182][183][184] and the cough Visual Analog Scale (cough VAS). 181,185 Several of the generic and sarcoid-specific HRQoL measures (SGRQ, 102 SHQ, 73 KSG, 92 and the SAT 53,54 ,) also include cough-related items.…”

Section: Coughmentioning

confidence: 99%

Health-Related Quality of Life in Sarcoidosis

Ndili

2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Health-related quality of life (HRQoL) describes an individual's perception of the impact of health, disease, and treatment on their quality of life (QoL). It is a reflection of how the manifestation of an illness and its treatment is personally experienced. Assessing HRQoL is particularly important in sarcoidosis because the attributable disease mortality is relatively low, and one of the major reasons for initiating treatment is to improve quality of life. HRQoL has been assessed in sarcoidosis using various generic and sarcoid-specific patient-reported outcome measures (PROMs). It is important that both the direct and indirect effects of the disease, as well as potential toxicities of therapy, are captured in the various PROMs used to assess HRQoL in sarcoidosis. This article provides a general overview of HRQoL in patients with sarcoidosis. It describes the various PROMs used to assess HRQoL in sarcoidosis and addresses the various factors that influence HRQoL in sarcoidosis. Specific attention is paid to fatigue, small fiber neuropathy, corticosteroid therapy, and other disease-specific factors that affect HRQoL in sarcoidosis. It also provides an insight into interventions that have been associated with improved HRQoL in sarcoidosis and offers suggestions for future research in this important area.

show abstract

“…The primary outcome is the cough-related QoL at 14 days after randomization. We will use the validated Leicester Cough Questionnaire (LCQ) score [18][19][20][21] to assess the impact of the study medication on patients' QoL (difference between arms measured 14 days after randomization). Total and individual LCQ domain scores will be calculated.…”

Section: Outcomes {12}mentioning

confidence: 99%

Oral corticosteroids for post-infectious cough in adults: study protocol for a double-blind randomized placebo-controlled trial in Swiss family practices (OSPIC trial)

Merlo

Essig

Brancati-Badarau

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundCough is a common reason for patients to visit general practices. So called post-infectious cough is defined as lasting 3 to 8 weeks after an upper respiratory tract infection. It can be disabling in daily activities, with substantial impact on physical and psychosocial health, leading to impaired quality of life and increased health care costs. Recommendations for the management of post-infectious cough in primary care are scarce and incoherent. A systematic review and meta-analysis of randomised clinical trials (RCT) assessing patient-relevant benefits and potential harms of available treatments identified six eligible RCTs assessing different treatment regimens (i.e. inhaled fluticasone propionate, inhaled budesonide, salbutamol plus ipratropium-bromide, montelukast, nociception-opioid-1-receptor agonist, codeine, gelatine). No RCT found clear patient-relevant benefits and most had an unclear or high risk of bias.Post-infectious cough is thought to be mediated by inflammatory processes that are also present in exacerbations of asthma or chronic obstructive pulmonary diseases for which there is strong evidence that oral corticosteroids provide patient-relevant benefit without relevant harm. We therefore plan to conduct the first RCT evaluating the effectiveness of oral corticosteroids for post-infectious cough.MethodsWe are conducting a triple-blinded randomised-controlled and multicentric superiority trial in primary health care practices in Switzerland. We will include 204 adult patients who consult their general practitioner (GP) for a cough lasting 3 to 8 weeks following an upper-respiratory tract infection. Participants will be randomly allocated to either the 5-day treatment with oral corticosteroids or placebo. The primary outcome is cough-related quality of life assessed by the Leicester Cough Questionnaire score 14 days after randomisation. Secondary outcomes include cough-related quality of life at several time points, overall cessation of cough and adverse events.DiscussionThis RCT will provide evidence on whether oral corticosteroids are beneficial and safe in patients with post-infectious cough. Results can have a substantial impact on the well-being and management of these patients in Switzerland and beyond. An evidence-based treatment for this condition may reduce re-consultations with GPs and spending for antitussive drugs, thus possibly having an impact on health care spending.Trial registrationClinicalTrials.gov NCT04232449, prospectively registered on 18 January 2020 (https://clinicaltrials.gov/ct2/show/NCT04232449).

show abstract

Psychometric properties of the German version of the Leicester Cough Questionnaire in sarcoidosis

Cited by 13 publications

References 51 publications

Psychometric characteristics of the Serbian version of the Licester Cough Questionnaire in sarcoidosis patients

Psychometric characteristics of the Serbian version of the Licester Cough Questionnaire in sarcoidosis patients

Health-Related Quality of Life in Sarcoidosis

Oral corticosteroids for post-infectious cough in adults: study protocol for a double-blind randomized placebo-controlled trial in Swiss family practices (OSPIC trial)

Contact Info

Product

Resources

About